Medeon Biodesign (6499) - Total Assets
Based on the latest financial reports, Medeon Biodesign (6499) holds total assets worth NT$1.68 Billion TWD (≈ $52.91 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Medeon Biodesign - Total Assets Trend (2017–2025)
This chart illustrates how Medeon Biodesign's total assets have evolved over time, based on quarterly financial data. Also see 6499 stock market capitalisation for the company's overall valuation and market capitalisation.
Medeon Biodesign - Asset Composition Analysis
Current Asset Composition (December 2025)
Medeon Biodesign's total assets of NT$1.68 Billion consist of 74.3% current assets and 25.7% non-current assets. Review 6499 liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 29.3% |
| Accounts Receivable | NT$39.26 Million | 2.2% |
| Inventory | NT$24.84 Million | 1.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Medeon Biodesign's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 6499 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Medeon Biodesign's current assets represent 74.3% of total assets in 2025, an increase from 70.9% in 2017.
- Cash Position: Cash and equivalents constituted 29.3% of total assets in 2025, up from 17.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
Medeon Biodesign Competitors by Total Assets
Key competitors of Medeon Biodesign based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677
|
China | CN¥1.63 Billion |
|
Autek China Inc
SHE:300595
|
China | CN¥6.40 Billion |
|
St.Shine Optical Co Ltd
TWO:1565
|
Taiwan | NT$7.81 Billion |
|
Safe Orthopaedics SA
PA:ALSAF
|
France | €11.81 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Medeon Biodesign - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.21 | 6.03 | 12.81 |
| Quick Ratio | 8.02 | 5.85 | 12.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.04 Billion | NT$927.67 Million | NT$2.26 Billion |
Medeon Biodesign - Advanced Valuation Insights
This section examines the relationship between Medeon Biodesign's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.11 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.2% |
| Total Assets | NT$1.78 Billion |
| Market Capitalization | $222.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Medeon Biodesign's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Medeon Biodesign's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Medeon Biodesign (2017–2025)
The table below shows the annual total assets of Medeon Biodesign from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.78 Billion ≈ $56.07 Million |
-5.22% |
| 2024-12-31 | NT$1.88 Billion ≈ $59.16 Million |
-31.65% |
| 2023-12-31 | NT$2.75 Billion ≈ $86.55 Million |
-32.00% |
| 2022-12-31 | NT$4.04 Billion ≈ $127.28 Million |
-7.43% |
| 2021-12-31 | NT$4.36 Billion ≈ $137.51 Million |
+31.69% |
| 2020-12-31 | NT$3.31 Billion ≈ $104.42 Million |
+31.68% |
| 2019-12-31 | NT$2.52 Billion ≈ $79.30 Million |
+29.25% |
| 2018-12-31 | NT$1.95 Billion ≈ $61.35 Million |
+18.87% |
| 2017-12-31 | NT$1.64 Billion ≈ $51.61 Million |
-- |
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more